论文部分内容阅读
Istaroxime(PST-2744;Debio-0614)是一种新型的、具有抑制Na+/K+-ATP酶和激动肌浆网钙泵双重作用的抗心衰药。其对Na+/K+-ATP酶的抑制导致心肌细胞内钙离子浓度升高,从而促进心肌细胞的收缩、使心跳强度增加。由于istaroxime促进心肌收缩的剂量与导致心律失常的剂量之间有较大
Istaroxime (PST-2744; Debio-0614) is a novel anti-heart failure drug that has the dual effect of inhibiting Na + / K + -ATPase and activating the sarcoplasmic reticulum calcium pump. The inhibition of Na + / K + -ATP enzyme leads to the increase of intracellular calcium concentration in cardiomyocytes, thereby promoting the contraction of cardiomyocytes and increasing the intensity of heartbeat. Because istaroxime promotes myocardial contractility between the dose and lead to a larger arrhythmia dose